Categories
COX

To date, it appears most Gram-negative bacteria contain both a thioredoxin and GSH system while most Gram-positive bacteria contain only a thioredoxin system (Lu and Holmgren, 2014)

To date, it appears most Gram-negative bacteria contain both a thioredoxin and GSH system while most Gram-positive bacteria contain only a thioredoxin system (Lu and Holmgren, 2014). target with broad spectrum antimicrobial activity. cysteine biosynthesis in fungi and many enteric bacteria (Gonzalez Porque et al., 1970; Russel et al., 1990). Drug Characteristics Arguably the best studied inhibitor of the thioredoxin system is auranofin, a gold complex originally approved to treat rheumatoid arthritis (Bombardier et al., 1986). Although thioredoxin reductase may not be the sole target for auranofin (Thangamani et al., 2016a), the drug is believed to inhibit this enzyme by irreversibly binding thiol and selenol groups on the enzyme (Fan et al., 2014). Ebselen is an organoselenium drug that acts as an antioxidant and an anti-inflammatory agent due to its GSH peroxidase-like activity (Muller et al., 1984; Schewe, 1995), and is a potent bacterial TrxR inhibitor via its binding to the C-terminal active site cysteine residue (Lu et al., 2013). 1-Methylpropyl 2-imidazolyl disulfide (PX-12) irreversibly binds to the Cys73 cysteine residue that lies outside the conserved redox catalytic site of Trx1 (Kirkpatrick et al., 1998). Initially tested as an antitumor drug, it was not approved due to lack of efficacy in human trials; although, it exhibited low MIF Antagonist toxicity (Ramanathan et al., 2011). Like most commonly used antibiotics, the common side effects of auranofin and PX-12 include nausea, lack of appetite, diarrhea, and stomach cramps (Furst, 1983; Cunha, 2001; Ramanathan et al., 2011). Ebselen has not shown adverse effects at the recommended dose (Singh et al., 2016). Please see Table ?Table11 for a list of pathogens these drugs have been tested against. For chemical structures of these inhibitors, see Figure ?Figure1C1C. Table 1 and studies of thioredoxin system inhibitors. (MRSA)Sanger 252MurinesystemicHarbut et al., 2015Auranofin(MRSA)132MurineAguinagalde et al., 2015Auranofinsp.KCTC 2625(MRSA)Sanger 252, TCH1516, ST-59, A7819, PA, D712A5940, X18311, PC-3, HIP 5836(VRE)VRE8 WMC, VRE 12-15-19 UCLA(MRSA)USA100, USA200, USA300which has two thioredoxins, a higher expressed Trx1 protein (encoded by (Ritz et al., 2000). However, some bacteria, such as (Pasternak et al., 1997), (Scharf et al., 1998), and (Muller and Buchanan, 1989) require a bacterial thioredoxin gene for survival. Redundant to the thioredoxin system in many bacteria is the glutaredoxin system which was initially identified as an alternative hydrogen donor for ribonucleotide reductase in an thioredoxin mutant (Holmgren, 1976). Simultaneous disruption of both thioredoxin and glutaredoxin systems is often lethal for bacteria (Prinz et al., 1997; Stewart et al., 1998). To date, it appears most Gram-negative bacteria contain both a thioredoxin and GSH system while most Gram-positive bacteria contain only a thioredoxin system (Lu and Holmgren, 2014). This highlights the critical role of thiol-redox homeostasis for microbial growth and further underscores antimicrobial drug potential. Bacterial thioredoxin CSH1 function and gene regulation has been reviewed previously (Zeller and Klug, 2006; Lu and Holmgren, 2014). Recent reports from animal studies have shed additional light on the important role of thioredoxin in bacterial pathogenesis. Cheng et al. (2017) propose that TrxA is essential for maintaining a highly reduced environment in the cytosol of providing a favorable environment for protein folding and subsequent activation. Furthermore, it was observed that TrxA is required for proper function of several key regulators, including (1) MogR, a DNA binding transcriptional repressor involved in flagella formation, and (2) PrfA, a member of the cAMP receptor protein (Crp) family of transcription factors which regulates several major virulence factors (ActA, LLO, and Hpt) of resulted in loss of motility and impairment of hemolytic activity greatly reducing virulence of this pathogen in mice. Thioredoxin also has been shown to play a role in the virulence of which uses secreted thioredoxin to reduce mucin molecules to their monomeric form decreasing mucin viscosity and allowing the organism to colonize as well as facilitating migration to the epithelial surface (Windle et al., 2000). Deletion of either the TrxA or TrxC genes in impairs the organisms ability to colonize the stomach following oral bacterial challenge (Kuhns et al., 2015). Lin et al. (2016), while studying a thioredoxin reductase (TrxB2) mutant, observed TrxB2 to be an essential thiol-reducing enzyme enzymatic assay, Harbut et al. (2015) clearly demonstrated that auranofin inhibited both recombinant thioredoxin reductases of and species. Auranofin was found to inhibit in bacteriostatic fashion at the MIC, but bactericidal at higher concentrations (Fuchs et al., 2016). A number of studies using have recognized auranofin as a potent antibacterial compound. Using an infection model, auranofin was shown to be protecting against via apparent targeting of the thioredoxin system (Fuchs et al., 2016). Auranofin and additional related gold-compounds also were shown to show significant inhibition against methicillin-resistant (MRSA) (Hokai et al., 2014). Animal studies carried out using.Additionally, ebselen analogs are effective against and spp. serve mainly because a useful restorative target with broad spectrum antimicrobial activity. cysteine biosynthesis in fungi and many enteric bacteria (Gonzalez Porque et al., 1970; Russel et al., 1990). Drug Characteristics Arguably the best analyzed inhibitor of the thioredoxin system is definitely auranofin, a platinum complex originally authorized to treat rheumatoid arthritis (Bombardier et al., 1986). Although thioredoxin reductase may not be the sole target for auranofin (Thangamani et al., 2016a), the drug is definitely believed to inhibit this enzyme by irreversibly binding thiol and selenol organizations within the enzyme (Lover et al., 2014). Ebselen is an organoselenium drug that functions as an antioxidant and an anti-inflammatory agent due to its GSH peroxidase-like activity (Muller et al., 1984; Schewe, 1995), and is a potent bacterial TrxR inhibitor via its binding to the C-terminal active site cysteine residue (Lu et al., 2013). 1-Methylpropyl 2-imidazolyl disulfide (PX-12) irreversibly binds to the Cys73 cysteine residue that lies outside the conserved redox catalytic site of Trx1 (Kirkpatrick et al., 1998). In the beginning tested as an antitumor drug, it was not approved due to lack of effectiveness in human tests; although, it exhibited low toxicity (Ramanathan et al., 2011). Like most popular antibiotics, the common side effects of auranofin and PX-12 include nausea, lack of hunger, diarrhea, and belly cramps (Furst, 1983; Cunha, 2001; Ramanathan et al., 2011). Ebselen has not shown adverse effects at the recommended dose (Singh et al., 2016). Please see Table ?Table11 for a list of pathogens these medicines have been tested against. For chemical structures of these inhibitors, see Number ?Figure1C1C. Table 1 and studies of thioredoxin system inhibitors. (MRSA)Sanger 252MurinesystemicHarbut et al., 2015Auranofin(MRSA)132MurineAguinagalde et al., 2015Auranofinsp.KCTC 2625(MRSA)Sanger 252, TCH1516, ST-59, A7819, PA, D712A5940, X18311, Personal computer-3, HIP 5836(VRE)VRE8 WMC, VRE 12-15-19 UCLA(MRSA)USA100, USA200, USA300which has two thioredoxins, a higher expressed Trx1 protein (encoded by (Ritz et al., 2000). However, some bacteria, such as (Pasternak et al., 1997), (Scharf et al., 1998), and (Muller and Buchanan, 1989) require a bacterial thioredoxin gene for survival. Redundant to the thioredoxin system in many bacteria is the glutaredoxin system which was in the beginning identified as an alternative hydrogen donor for ribonucleotide reductase in an thioredoxin mutant (Holmgren, 1976). Simultaneous disruption of both thioredoxin and glutaredoxin systems is definitely often lethal for bacteria (Prinz et al., 1997; Stewart et al., 1998). To day, it appears most Gram-negative bacteria consist of both a thioredoxin and GSH system while most Gram-positive bacteria consist of only a thioredoxin system (Lu and Holmgren, 2014). This shows the critical part of thiol-redox homeostasis for microbial growth and further underscores antimicrobial drug potential. Bacterial thioredoxin function and gene rules has been examined previously (Zeller and Klug, 2006; Lu and Holmgren, 2014). Recent reports from animal studies have shed additional light within the important part of thioredoxin in bacterial pathogenesis. Cheng et al. (2017) propose that TrxA is essential for maintaining a highly reduced environment in the cytosol of providing a favorable environment for protein folding and subsequent activation. Furthermore, it was observed that TrxA is required for appropriate function of several important regulators, including (1) MogR, a DNA binding transcriptional repressor involved in flagella formation, and (2) PrfA, a member of the cAMP receptor protein (Crp) family of transcription factors which regulates several major virulence factors (ActA, LLO, and Hpt) of resulted in loss of motility and impairment of hemolytic activity greatly reducing virulence of this pathogen in mice. Thioredoxin also has been shown to play a role in the virulence of which uses secreted thioredoxin to MIF Antagonist MIF Antagonist reduce mucin molecules to their monomeric form reducing mucin viscosity and permitting the.